Navigation Links
Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
Date:11/15/2010

BASKING RIDGE, N.J., Nov. 15, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced today two abstract presentations evaluating the potency and duration of a subcutaneous depot formulation of pegnivacogin (a.k.a. RB006), a nuclease-stabilized aptamer and direct Factor IXa inhibitor.  The studies were presented at the American Heart Association (AHA) Scientific Sessions meeting, on November 15, 2010.  

At 9:15 a.m. CST, Christopher Rusconi, Ph.D., Senior Vice President and Chief Scientific Officer, presented an abstract titled "Subcutaneous Administration of the Direct FIXa Inhibitor RB006 Provides Persistent Inhibition of Thrombin Generation."  The study examined the effects of RB006 in 28 healthy volunteers who received a single dose of 0.5, 1.0 or 3mg/kg RB006 or placebo administered subcutaneously. Results demonstrated potent, dose dependent inhibition of thrombin generation, which persisted through seven days, supporting dosing of no more than once a week.

At 11:00 a.m. CST, Steven L. Zelenkofske, D.O, F.A.C.C., Senior Vice President and Chief Medical Officer, presented an abstract titled "RB006 a Direct FIXa Inhibitor Provides Potent Concentration Dependent Suppression of Thrombin Generation."  This study was intended to better define potential dosing ranges of RB006 for future venous thromboembolism (VTE) studies.  Results revealed that while very low plasma concentrations of RB006 were needed to substantially affect the kinetics and extent of thrombin generation, very high levels of thrombin suppression could be achieved at higher plasma concentrations

The data from both abstracts are promising for future development of Regado's REG2 anticoagulant system, which consists of a subcutaneously administered depot formulation of RB006 paired with its matched active control agent, an IV bolus formulation of anivamersen (a.k.a. RB007).

Both abstracts were coauthored by Steven L. Zelenkofske, D.O., Christopher P. Rusconi, Ph.D., Carolyn M. Darmiento, MS, all from Regado Biosciences; and Richard C. Becker, MD, Duke University School of Medicine, Durham, NC; Thomas L. Ortel, M.D., Ph.D., Director, Duke Clinical Coagulation and Platelet Immunology Laboratories; and William Wargin, Ph.D. President of PK-PM Associates, LLC.

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, presently in a phase 2b clinical trial (the RADAR trial), is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients intended for Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy.  Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.

ABOUT APTAMERSPegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.   A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing its biologic effects.  Anivamersen is the active control agent of pegnivacogin.  

More information can be found at www.regadobio.comContact:Ellen McDonald, Chief Business Officer, Regado Biosciences, 1-908-580-2113, emcdonald@regadobio.comMedia Contact:Tiberend Strategic Advisors, Inc.1-212-827-0020Andrew Mielach, amielach@tiberendstrategicadvisors.com
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
2. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
3. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
4. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
5. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
6. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
7. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
8. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
9. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
10. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
11. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:8/4/2017)... The search for test results that can ... has long been the goal of healthcare providers and ... the largest meeting of lab professionals and IVD firms ... firm Kalorama Information.  The firm said scores of companies ... supplies and software were at the American Association for ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital ... services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... that uses UVC light energy to kill deadly pathogens such as C. diff , ... Tru-D SmartUVC ... Tru-D in action in a patient ...
Breaking Medicine Technology:
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Wilderness Voices”: ... of world travel. “Wilderness Voices” is the creation of published author, Martha McKown, ... Martha McKown was inspired as a very young child when her older sisters studied ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... Stewart is the Founder and Managing Member for t4 Leadership Development & Consulting. ... critical to his definition of “success”: physician leadership development, servant leadership, data driven ...
(Date:8/21/2017)... (PRWEB) , ... August 22, 2017 , ... PracticeMatch, a ... to help healthcare employers connect with physicians and advanced practitioners like nurse practitioners ... career fairs in August through November of this year. The online career fairs ...
(Date:8/21/2017)... , ... August 21, 2017 , ... FCPX LUT Monochromatic ... Editors can quickly and easily add washed color grades to footage. A LUT is ... changes every pixel’s color to the corresponding color indicated by the table. This pack ...
(Date:8/21/2017)... ... August 21, 2017 , ... Duncan Insurance Agency ... the people of Michigan. The new initiative fundraises for the Kalamazoo Humane Society ... forefront of animal protection and welfare by addressing the root causes of pet ...
Breaking Medicine News(10 mins):